<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BRN</journal-id>
<journal-id journal-id-type="hwp">spbrn</journal-id>
<journal-id journal-id-type="nlm-ta">Biol Res Nurs</journal-id>
<journal-title>Biological Research For Nursing</journal-title>
<issn pub-type="ppub">1099-8004</issn>
<issn pub-type="epub">1552-4175</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1099800411405030</article-id>
<article-id pub-id-type="publisher-id">10.1177_1099800411405030</article-id>
<title-group>
<article-title>Tridimensional Personalities and Polymorphism of Dopamine D2 Receptor Among Heroin Addicts</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Teh</surname>
<given-names>Lay K.</given-names>
</name>
<degrees>BPharm, MPharm, PhD</degrees>
<xref ref-type="aff" rid="aff1-1099800411405030">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Izuddin</surname>
<given-names>Abu F.</given-names>
</name>
<degrees>BSc, MSc</degrees>
<xref ref-type="aff" rid="aff1-1099800411405030">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
 <surname>M. H.</surname>
 <given-names>Fazleen H.</given-names>
</name>
<degrees>BSc, MSc</degrees>
<xref ref-type="aff" rid="aff1-1099800411405030">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zakaria</surname>
<given-names>Zainul A.</given-names>
</name>
<degrees>BSc, PhD</degrees>
<xref ref-type="aff" rid="aff1-1099800411405030">1</xref>
<xref ref-type="aff" rid="aff2-1099800411405030">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Salleh</surname>
<given-names>Mohd. Zaki</given-names>
</name>
<degrees>BSc, MSc, PhD</degrees>
<xref ref-type="aff" rid="aff1-1099800411405030">1</xref>
<xref ref-type="corresp" rid="corresp1-1099800411405030"/>
</contrib>
</contrib-group>
<aff id="aff1-1099800411405030"><label>1</label>Pharmacogenomics Centre (PROMISE), Faculty of Pharmacy, Universiti Teknologi MARA, Kuala, Selangor, Malaysia</aff>
<aff id="aff2-1099800411405030"><label>2</label>Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia</aff>
<author-notes>
<corresp id="corresp1-1099800411405030">Mohd. Zaki Salleh, Pharmacogenomics Centre (PROMISE), Faculty of Pharmacy, Universiti Teknologi, MARA 42300 Puncak Alam, Selangor DE, Malaysia Email: <email xlink:type="simple">zakisalleh@puncakalam.uitm.edu.my</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<fpage>188</fpage>
<lpage>196</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>
<bold>Background:</bold> Drug addiction is a multifactorial disorder. Researchers have posited that an individual’s inherited behavioral propensity or temperament contributes to the disorder by shaping a personality strongly linked with the risk of drug abuse. Further, they hypothesize that the polymorphism of dopamine D2 receptor increases the susceptibility to and severity of addiction. We, therefore, investigated possible associations between dopamine D2 receptor (DRD2) and personality traits among intravenous heroin addicts. <bold>Methods:</bold> We assessed 93 intravenous heroin addicts and controls using Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) and the Tridimensional Personality Questionnaire (TPQ). We confirmed drug-dependence status using a questionnaire based on DSM-IV criteria. We extracted DNA from the subjects’ whole blood and genotyped it for <italic>DRD2</italic> allelic variants. <bold>Results:</bold> Genotype analysis showed a significantly higher frequency for the TaqIA polymorphism among the addicts (69.9%) compared to control subjects (42.6%; Fisher’s exact χ<sup>2</sup>, <italic>p</italic> &lt; .05). We observed no significant differences for other variants between the addicts and controls. The addicts had higher scores for novelty seeking (NS) and harm avoidance (HA) personality traits but lower scores for reward dependence (RD) when compared to control subjects. <bold>Limitation:</bold> The environmental cues are different for the addicts, and the healthy university students we used as controls. We recommend that researchers employ a gene-environment interaction approach to study factors associated with addictive behaviors in future studies. <bold>Conclusion:</bold> Taq1A may be implicated for an increased vulnerability to addiction. Screening of this marker might be useful for identifying individuals at risk of addiction.</p>
</abstract>
<kwd-group>
<kwd>Tridimensional Personality Questionnaire (TPQ)</kwd>
<kwd>heroin addicts</kwd>
<kwd>Taq1A</kwd>
<kwd>dopamine D2 receptor (DRD2)</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Drug addiction is a chronic, multifactorial, relapsing disorder involving the compulsive behaviors of drug seeking and taking, which persist despite serious negative consequences (<xref ref-type="bibr" rid="bibr27-1099800411405030">Smith &amp; Seymour, 2001</xref>). Biological, psychological, social, and environmental factors all play a role in this disorder. Researchers hypothesize that an individual’s inherited behavioral propensity or temperament contribute to shaping a personality that is strongly associated with the risk of drug abuse and addiction (<xref ref-type="bibr" rid="bibr23-1099800411405030">Moyer, 1992</xref>).</p>
<p>Several researchers have hypothesized that individual differences in level of vulnerability to substance abuse may be due, in part, to different alleles of the dopamine D2 receptor gene (<xref ref-type="bibr" rid="bibr6-1099800411405030">Blum et al., 1990</xref>; <xref ref-type="bibr" rid="bibr37-1099800411405030">Zhang et al., 2007</xref>). <italic>TaqIA</italic> alleles have been associated with a number of impulsive, addictive, or compulsive disorders and behaviors such as alcoholism, nicotine and cocaine dependence, obesity, and multiple-substance abuse (<xref ref-type="bibr" rid="bibr22-1099800411405030">Lawford et al., 2000</xref>; <xref ref-type="bibr" rid="bibr28-1099800411405030">Smith, Watson, Gates, Ball, &amp; Foxcroft, 2007</xref>; <xref ref-type="bibr" rid="bibr30-1099800411405030">Spitz et al., 1998</xref>). For example, <xref ref-type="bibr" rid="bibr14-1099800411405030">Foll, Gallo, Strat, Lu, and Gorwood (2009)</xref> reported that the addiction phenotype is critically influenced by genetic variation in dopaminergic receptors. Gene-dose effect suggests that A1+ homozygotes have a lower number of dopamine receptor D2-binding sites than A2 homozygotes; A1+ homozygotes thus have limited availability of intrinsic dopamine and enhanced reward induced by dopaminergic agents, which may lead to addiction (<xref ref-type="bibr" rid="bibr30-1099800411405030">Spitz et al., 1998</xref>). In one recent study, <xref ref-type="bibr" rid="bibr20-1099800411405030">Hou and Li (2009)</xref> found that the variation of DRD2 TaqIA was significantly associated with heroin-dependent status in the North China, Han ethnic population.</p>
<p>In addition to genetic factors, researchers have also reported that personality plays an important role in the predisposition for and precipitation and perpetuation of substance use disorders (<xref ref-type="bibr" rid="bibr16-1099800411405030">Gerra et al., 2008</xref>). Furthermore, genetic factors may influence personality. The three scales of the TPQ—novelty seeking (NS), harm avoidance (HA), and reward dependence (RD)—are associated with distinct neurotransmitters, and an individual’s genetic profile determines the expression of these substances.</p>
<p>The purpose of the present study was to examine individual differences and levels of vulnerability in substance abuse in relation to the 3 TPQ scales and genetic polymorphism of DRD2 (<xref ref-type="bibr" rid="bibr21-1099800411405030">Kreek, Bart, Lilly, Laforge, &amp; Nielsen, 2005</xref>). This was the first study conducted in Malaysia to investigate the relevance of TPQ and gene polymorphism in addiction. We hope to provide insight into the factors involved in drug addiction and aid policy makers in designing programs for the prevention, treatment, and rehabilitation of addicts.</p>
<sec id="section1-1099800411405030">
<title>Material and Method</title>
<p>The local Research Ethics Committee approved this study. We explained the details of the study to all participants and obtained written consents.</p>
<sec id="section2-1099800411405030">
<title>Study Design</title>
<p>We recruited male intravenous heroin addicts from a drop-in shelter and a private clinic in Malaysia. We interviewed participants using a questionnaire based on Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) criteria, to diagnose drug addiction status, and the TPQ, to assess their personalities, and drew blood samples for genotype analysis. We administered the same questionnaires to a control group comprising 101 healthy university students with no history of drug or alcohol abuse or dependence, excluding females and those with severe cognitive impairment or mental retardation.</p>
</sec>
<sec id="section3-1099800411405030">
<title>Blood Samples</title>
<p>We drew 10 ml of blood from each participant into a vacutainer containing 4% sodium citrate. We kept the samples on ice during transportation and stored them at −70°C until DNA extraction.</p>
</sec>
<sec id="section4-1099800411405030">
<title>DSM-IV Questionnaire</title>
<p>The DSM-IV questionnaire that we used to confirm drug addiction among participants consists of eight yes/no questions. The DSM-IV criteria for drug dependence include manifestation of three or more of the eight listed maladaptive behaviors within a 12-month period, leading to significant clinical impairment and distress (<xref ref-type="bibr" rid="bibr32-1099800411405030">Tyndale, Droll, &amp; Sellers, 1997</xref>).</p>
</sec>
<sec id="section5-1099800411405030">
<title>TPQ</title>
<p>The TPQ is a 100-item true/false instrument that takes about 15 min to complete. Investigators have used it in various studies of personality characteristics among addicts (<xref ref-type="bibr" rid="bibr9-1099800411405030">Cloninger, 1987b</xref>; <xref ref-type="bibr" rid="bibr36-1099800411405030">Vukov, Baba-Milkic, &amp; Lecic, 1995</xref>). We translated the questionnaire into the Malay language and tested their validity using the following procedure: We administered the Malay-language version to 20 individuals. After a week, we administered the English version to the same individuals. We scored both versions of the questionnaires, modified sentences that were difficult to understand based on participant feedback, and retested the questionnaire as described above to achieve a reliability level of .60. The questionnaire assesses three major personality scales, as follows. Scores for each subscale are summed to get the total score for each scale:<list list-type="simple">
<list-item>
<p>NS scale</p>
</list-item>
<list-item>
<p>NS1: exploratory excitability versus stoic rigidity (9 items)</p>
</list-item>
<list-item>
<p>NS2: impulsiveness versus reflection (8 items)</p>
</list-item>
<list-item>
<p>NS3: extravagance versus reserve (7 items)</p>
</list-item>
<list-item>
<p>NS4: disorderliness versus regimentation (10 items)</p>
</list-item>
<list-item>
<p>HA scale:</p>
</list-item>
<list-item>
<p>HA1: anticipatory worry and pessimism (10 items)</p>
</list-item>
<list-item>
<p>HA2: fear of uncertainty (7 items)</p>
</list-item>
<list-item>
<p>HA3: shyness with strangers (7 items)</p>
</list-item>
<list-item>
<p>HA4: fatigability and asthenia (10 items)</p>
</list-item>
<list-item>
<p>Reward dependence (RD) scale:</p>
</list-item>
<list-item>
<p>RD1: sentimentality (5 items)</p>
</list-item>
<list-item>
<p>RD2: persistence (9 items)</p>
</list-item>
<list-item>
<p>RD3: attachment (11 items)</p>
</list-item>
<list-item>
<p>RD4: dependence (5 items)</p>
</list-item>
</list>We computed mean scores for each of the subscales and scales via Statistical Package for Social Sciences (SPSS) and compared the means for the drug-addiction group with those of controls. We also calculated Cronbach’s coefficient α, a measure of internal consistency, for each of the scales and subscales to determine the reliability of the results. An acceptable level of reliability was ≤.60 (<xref ref-type="bibr" rid="bibr13-1099800411405030">Dawson-Sanders &amp; Trapp, 1994</xref>).</p>
</sec>
<sec id="section6-1099800411405030">
<title>Analysis of DRD2 Gene Polymorphism by Polymerase Chain Reaction (PCR)</title>
<p>We screened each sample for eight alleles in four sets of reactions to detect allelic variants for Val<sub>96</sub>Ala, Val<sub>154</sub>Ile, Leu<sub>141</sub>Leu (from exon 3 to 4), Pro<sub>310</sub>Ser, Ser<sub>311</sub>Cys (from exon 7), -141C Ins/Del, A-241G (from promoter region, i.e., 5′-untranslated region), and TaqIA (from TaqIA region, i.e., 3′-untranslated region) using a two-step allele-specific PCR procedure.</p>
<p>We carried out all the reactions in a final volume of 25 μl in a buffer consisting of 10 mM Tris-HCl (pH 8.0), 50 mM KCl, 1 mM EDTA, 0.1% Triton X-100, and 50% glycerol (v/v). In the amplification of the first PCR product, we carried out the reactions in the presence of 2.0 mM MgCl<sub>2</sub>, 0.2 mM of each dNTPs, 0.5 U of Taq DNA polymerase (Biotool<sup>®</sup>, Biotechnological &amp; Medical Laboratories, S.A., Spain), and their respective primers at varying concentrations, as listed in <xref ref-type="table" rid="table1-1099800411405030">Table 1</xref>
. We used 200 ng of DNA as the template. We performed amplification in a thermal cycler (Gradient PCR, Takara Bio, Inc., Japan) by subjecting the template/primers preparation to 1 cycle of hot start PCR at 94°C for 2 min and 35 cycles at 94°C for 1 min, 65°C for 1 min, and 72°C for 2 min. We included a final extension reaction at 72°C for 7 min. We analyzed 8 μl of the first PCR product on 1.5% agarose gels and 1× TBE.</p>
<table-wrap id="table1-1099800411405030" position="float">
<label>Table 1.</label>
<caption>
<p>Primer Sequences for PCR Genotyping of Dopamine D2 Receptor Gene</p>
</caption>
<graphic alt-version="no" alternate-form-of="table1-1099800411405030" position="float" xlink:href="10.1177_1099800411405030-table1.tif" xlink:type="simple"/>
<table>
<thead>
<tr>
<th colspan="1" rowspan="1">Exon/Fragments</th>
<th colspan="1" rowspan="1">Primer Name</th>
<th colspan="1" rowspan="1">Primer Sequences (5′-3′)</th>
<th colspan="1" rowspan="1">Calculated Melting Temperature (°C)</th>
<th align="center" colspan="1" rowspan="1">Fragment Size (bp)</th>
<th align="center" colspan="1" rowspan="1">Primer Concentrations (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6" rowspan="1">Primers for allele-specific PCR genotyping</td>
</tr>
<tr>
<td colspan="6" rowspan="1"> Exon 3 to 4</td>
</tr>
<tr>
<td colspan="1" rowspan="2">1st PCR</td>
<td colspan="1" rowspan="1">Ex 3 to 4 Fw</td>
<td colspan="1" rowspan="1">cag ctg cct cct gag tct gt</td>
<td colspan="1" rowspan="1">64</td>
<td colspan="1" rowspan="1">1,497</td>
<td colspan="1" rowspan="1">0.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ex 3 to 4 Rv</td>
<td colspan="1" rowspan="1">cca tat ctg tgc cag gga ct</td>
<td colspan="1" rowspan="1">62</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.5</td>
</tr>
<tr>
<td colspan="1" rowspan="6">2nd PCR</td>
<td colspan="1" rowspan="1">Val<sub>96</sub>Ala wt</td>
<td colspan="1" rowspan="1">tgt tgc ttt gtc ccc agg t</td>
<td colspan="1" rowspan="1">58</td>
<td colspan="1" rowspan="1">1,387</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Val<sub>96</sub>Ala mut</td>
<td colspan="1" rowspan="1">tgt tgc ttt gtc ccc agg c</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Val<sub>154</sub>Ile wt</td>
<td colspan="1" rowspan="1">caa gcg ccg ggt cac cg</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">225</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Val<sub>154</sub>Ile mut</td>
<td colspan="1" rowspan="1">caa gcg ccg ggt cac ca</td>
<td colspan="1" rowspan="1">58</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Leu<sub>141</sub>Leu wt</td>
<td colspan="1" rowspan="1">ctg tgg cca tgc cca tgc</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">225</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Leu<sub>141</sub>Leu mut</td>
<td colspan="1" rowspan="1">ctg tgg cca tgc cca tgt</td>
<td colspan="1" rowspan="1">58</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="6" rowspan="1"> Exon 7</td>
</tr>
<tr>
<td colspan="1" rowspan="2">1st PCR</td>
<td colspan="1" rowspan="1">Ex 7 Fw</td>
<td colspan="1" rowspan="1">ctg atg cct ggg aac ttg tc</td>
<td colspan="1" rowspan="1">62</td>
<td colspan="1" rowspan="1">566</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ex 7 Rv</td>
<td colspan="1" rowspan="1">gcc cat ctg taa agt gag ca</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="4">2nd PCR</td>
<td colspan="1" rowspan="1">Ser<sub>311</sub>Cys wt</td>
<td colspan="1" rowspan="1">tga ctc tcc ccg acc cgt c</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">409</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ser<sub>311</sub>Cys mut</td>
<td colspan="1" rowspan="1">tga ctc tcc ccg acc cgt g</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pro<sub>310</sub>Ser wt</td>
<td colspan="1" rowspan="1">gct gac tct ccc cga cc</td>
<td colspan="1" rowspan="1">58</td>
<td colspan="1" rowspan="1">411</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pro<sub>310</sub>Ser mut</td>
<td colspan="1" rowspan="1">gct gac tct ccc cga ct</td>
<td colspan="1" rowspan="1">56</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="6" rowspan="1"> TaqIA (3′-region)</td>
</tr>
<tr>
<td colspan="1" rowspan="2">1st PCR</td>
<td colspan="1" rowspan="1">TaqIA Fw</td>
<td colspan="1" rowspan="1">acg gct ggc caa gtt gtc t</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">305</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TaqIA Rv</td>
<td colspan="1" rowspan="1">acc ttc ctg agt gtc atc aac</td>
<td colspan="1" rowspan="1">62</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="2">2nd PCR</td>
<td colspan="1" rowspan="1">TaqIA wt</td>
<td colspan="1" rowspan="1">atc ctc aaa gtg ctg gtc g</td>
<td colspan="1" rowspan="1">58</td>
<td colspan="1" rowspan="1">197</td>
<td colspan="1" rowspan="1">0.3</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TaqIA mut</td>
<td colspan="1" rowspan="1">atc ctc aaa gtg ctg gtc a</td>
<td colspan="1" rowspan="1">56</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.3</td>
</tr>
<tr>
<td colspan="6" rowspan="1"> Promoter region (5′-region)</td>
</tr>
<tr>
<td colspan="1" rowspan="2">1st PCR</td>
<td colspan="1" rowspan="1">PR Fw</td>
<td colspan="1" rowspan="1">act ggc gag cag acg gtg a</td>
<td colspan="1" rowspan="1">62</td>
<td colspan="1" rowspan="1">276</td>
<td colspan="1" rowspan="1">0.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PR Rv</td>
<td colspan="1" rowspan="1">tga agc tgg aca gct ctg c</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.4</td>
</tr>
<tr>
<td colspan="1" rowspan="4">2nd PCR</td>
<td colspan="1" rowspan="1">-141C Ins/Del wt</td>
<td colspan="1" rowspan="1">aac ccc tcc tac ccg ttc c</td>
<td colspan="1" rowspan="1">62</td>
<td colspan="1" rowspan="1">151</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">-141C Ins/Del mut</td>
<td colspan="1" rowspan="1">aac ccc tcc tac ccg ttc a</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">A-241G wt</td>
<td colspan="1" rowspan="1">cag cct gca atc aca gct ta</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">252</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">A-241G mut</td>
<td colspan="1" rowspan="1">cag cct gca atc aca gct tg</td>
<td colspan="1" rowspan="1">62</td>
<td colspan="1" rowspan="1">
</td>
<td colspan="1" rowspan="1">0.25</td>
</tr>
<tr>
<td colspan="6" rowspan="1">Primers for positive controls</td>
</tr>
<tr>
<td colspan="1" rowspan="3"> Exon 3 to 4</td>
<td colspan="1" rowspan="1">Val<sub>96</sub>Ala</td>
<td colspan="1" rowspan="1">TGCTTTGTCCCCAGGC GGTAGGTGAGTGGA</td>
<td colspan="1" rowspan="1">96</td>
<td colspan="1" rowspan="1">n/a</td>
<td colspan="1" rowspan="1">n/a</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Val<sub>154</sub>Ile</td>
<td colspan="1" rowspan="1">AAGCGCCGGGTCACC ATCATGATCTCCATC</td>
<td colspan="1" rowspan="1">91</td>
<td colspan="1" rowspan="1">n/a</td>
<td colspan="1" rowspan="1">n/a</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Leu<sub>141</sub>Leu</td>
<td colspan="1" rowspan="1">GTGGCCATGCCCATGT TGTACAATACGCGC</td>
<td colspan="1" rowspan="1">91</td>
<td colspan="1" rowspan="1">n/a</td>
<td colspan="1" rowspan="1">n/a</td>
</tr>
<tr>
<td colspan="1" rowspan="2">Exon 7</td>
<td colspan="1" rowspan="1">Ser<sub>311</sub>Cys</td>
<td colspan="1" rowspan="1">CTCTCCCCGACCCGTG CCACCAYGGTCTCC</td>
<td colspan="1" rowspan="1">100</td>
<td colspan="1" rowspan="1">n/a</td>
<td colspan="1" rowspan="1">n/a</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pro<sub>310</sub>Ser</td>
<td colspan="1" rowspan="1">CTGACTCTCCCCGACT CGTCCCACCAYGGT</td>
<td colspan="1" rowspan="1">96</td>
<td colspan="1" rowspan="1">n/a</td>
<td colspan="1" rowspan="1">n/a</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TaqIA region</td>
<td colspan="1" rowspan="1">TaqIA</td>
<td colspan="1" rowspan="1">CTCAAAGTGCTGGTCA AGGCAGGCGCCCAG</td>
<td colspan="1" rowspan="1">98</td>
<td colspan="1" rowspan="1">n/a</td>
<td colspan="1" rowspan="1">n/a</td>
</tr>
<tr>
<td colspan="1" rowspan="2">Promoter region</td>
<td colspan="1" rowspan="1">-141C Ins/Del</td>
<td colspan="1" rowspan="1">CCCTCCTACCCGTTCA GGCCGGGGATCGCC</td>
<td colspan="1" rowspan="1">104</td>
<td colspan="1" rowspan="1">n/a</td>
<td colspan="1" rowspan="1">n/a</td>
</tr>
<tr>
<td colspan="1" rowspan="1">A-241G</td>
<td colspan="1" rowspan="1">CTGCAATCACAGCTTGT TACTCTGGGTGTG</td>
<td colspan="1" rowspan="1">94</td>
<td colspan="1" rowspan="1">n/a</td>
<td colspan="1" rowspan="1">n/a</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1099800411405030">
<p>
<italic>Note</italic>. n/a = not applicable; PCR = polymerase chain reaction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We diluted the first PCR amplicons to 1 in 50 with autoclaved Mili-Q water and then used 2 μl of this product as templates in the second-step PCR. We performed seven sets of parallel allele-specific reactions to detect eight different alleles: Set A (Val<sub>96</sub>Ala and Val<sub>154</sub>Ile), Set B (Leu<sub>141</sub>Leu), Set C (Pro<sub>310</sub>Ser), Set D (Pro<sub>310</sub>Ser), Set E (-141C Ins/Del), Set F (A-241G), and Set G (TaqIA).</p>
<p>We used the same buffer as described above for the first-step PCR and, as before, performed the reactions in the presence of 1.0 mM MgCl<sub>2</sub>, 0.2 mM of each dNTPs, 0.5 U of Taq DNA polymerase, and their respective primers at various concentrations (<xref ref-type="table" rid="table1-1099800411405030">Table 1</xref>). For amplification of the second PCR, we performed 15 cycles on the thermal cycler using the following temperatures and durations: 94°C for 1 min, 63°C for 1 min, and 72°C for 2 min. We optimized the cycling condition and reaction components to obtain the highest possible yield and specificity. We analyzed 8 μl of the second PCR product on 1.5% agarose gels and 1× TBE.</p>
<p>We generated positive controls for use in the method optimization step and subsequently in PCR reactions. The primers used for positive controls are listed in <xref ref-type="table" rid="table1-1099800411405030">Table 1</xref>. We included a positive and negative control (autoclaved distilled Mili-Q) for each PCR batch to avoid false-positive or false-negative results. When results were inconclusive, we repeated the PCR procedure for that sample.</p>
<p>We validated the results obtained from PCR analysis by direct DNA sequencing using the same primers as for the first PCR. We purified the DNA samples using a QIAquickR PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced them on ABI 3700 using BigDyeR Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA). We aligned the DNA sequences and compared them with the gene sequence from the National Center for Biotechnology Information (NCBI) GenBank (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/genbank/" xlink:type="simple">http://www.ncbi.nlm.nih.gov/genbank/</ext-link>).</p>
</sec>
<sec id="section7-1099800411405030">
<title>Statistical Analysis</title>
<p>We performed descriptive summaries (means and frequencies) and comparative statistics (Fisher’s exact χ<sup>2</sup>, <italic>t</italic> test and analysis of variance [ANOVA]). For each of the TPQ scales and subscales, we also calculated Cronbach’s coefficient α. We performed all analyses using the SPSS<sup>®</sup> version 13 software on an IBM-compatible computer.</p>
</sec>
</sec>
<sec id="section8-1099800411405030">
<title>Results</title>
<sec id="section9-1099800411405030">
<title>DSM-IV and Sociodemographic Data</title>
<p>We recruited 93 intravenous heroin addicts using convenience sampling over a 6-month period. No one that we approached refused to participate once we explained the purpose of the study and assured them of subject confidentiality. All participants met the DSM-IV criteria for drug dependence. However, they differed in terms of the number of criteria met, with 54% meeting all 7, 34% meeting 6, 8% meeting 5, 3% meeting 4, and 1% meeting 3. The mean age of the participants was 34.5 ± 9.2 years, with the oldest being 57 and the youngest 20 years old; 27% were married, 65% were single, 4% were divorcees, and 4% were widows. Of those who were married, 92% lived with their spouse, while 8% did not. We present the sociodemographic characteristics of the participants in <xref ref-type="table" rid="table2-1099800411405030">Table 2</xref>
.</p>
<table-wrap id="table2-1099800411405030" position="float">
<label>Table 2.</label>
<caption>
<p>Demographic Information for IVDU (n = 93) Versus Healthy Controls (n = 101)<sup>
<xref ref-type="table-fn" rid="table-fn3-1099800411405030">a</xref></sup>
</p>
</caption>
<graphic alt-version="no" alternate-form-of="table2-1099800411405030" position="float" xlink:href="10.1177_1099800411405030-table2.tif" xlink:type="simple"/>
<table>
<thead>
<tr>
<th colspan="1" rowspan="1">Variable</th>
<th colspan="1" rowspan="1">IVDU <italic>N</italic> (%)</th>
<th colspan="1" rowspan="1">Healthy Control, <italic>N</italic> (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3" rowspan="1">Country of origin</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Malaysia</td>
<td colspan="1" rowspan="1">92 (98.9)</td>
<td colspan="1" rowspan="1">101 (100)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Singapore</td>
<td colspan="1" rowspan="1">1 (1.1)</td>
<td colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td colspan="3" rowspan="1">Years of education</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &lt;10</td>
<td colspan="1" rowspan="1">44 (47.3)</td>
<td colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ≥10</td>
<td colspan="1" rowspan="1">49 (52.7)</td>
<td colspan="1" rowspan="1">101 (100)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Smoking—yes</td>
<td colspan="1" rowspan="1">92 (98.9)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Alcohol consumption—yes</td>
<td colspan="1" rowspan="1">27 (29.0)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="3" rowspan="1">Martial status</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Single</td>
<td colspan="1" rowspan="1">60 (64.5)</td>
<td colspan="1" rowspan="1">101 (100)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Married</td>
<td colspan="1" rowspan="1">25 (26.9)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Divorced</td>
<td colspan="1" rowspan="1">4 (4.3)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Widowed</td>
<td colspan="1" rowspan="1">4 (4.3)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="3" rowspan="1">Employment</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Permanent job</td>
<td colspan="1" rowspan="1">17 (18.3)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Temporary job</td>
<td colspan="1" rowspan="1">61 (65.6)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Family business/farm</td>
<td colspan="1" rowspan="1">3 (3.2)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Self-employed</td>
<td colspan="1" rowspan="1">11 (11.8)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Government welfare</td>
<td colspan="1" rowspan="1">1 (1.1)</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> University student</td>
<td colspan="1" rowspan="1">0</td>
<td colspan="1" rowspan="1">101 (100)</td>
</tr>
<tr>
<td colspan="3" rowspan="1">Social class at birth<sup><xref ref-type="table-fn" rid="table-fn4-1099800411405030">b</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Upper class</td>
<td colspan="1" rowspan="1">10 (10.8)</td>
<td colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Upper middle class</td>
<td colspan="1" rowspan="1">28 (30.1)</td>
<td colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Lower middle class</td>
<td colspan="1" rowspan="1">41 (44.1)</td>
<td colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Lower class</td>
<td colspan="1" rowspan="1">14 (15.0)</td>
<td colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td colspan="3" rowspan="1">Current social class</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Upper middle class</td>
<td colspan="1" rowspan="1">21 (22.6)</td>
<td colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Lower middle class</td>
<td colspan="1" rowspan="1">34 (36.6)</td>
<td colspan="1" rowspan="1">
</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Lower class</td>
<td colspan="1" rowspan="1">38 (40.8)</td>
<td colspan="1" rowspan="1">
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1099800411405030">
<p>
<italic>Note</italic>. IVDUs = intravenous drug users.</p>
</fn>
<fn id="table-fn3-1099800411405030">
<p>
<sup>a</sup>All participants were male and identified themselves as Malay.</p>
</fn>
<fn id="table-fn4-1099800411405030">
<p>
<sup>b</sup>Social class is based on annual income, as follows: upper class = highly educated (often with graduate degrees) professionals and managers; upper middle class = semi-professionals and craftsmen with some stable income; lower middle class = clerical and other workers with lower job security; lower class = those who occupy poorly paid positions or rely on government welfare. We did not perform this classification on the university students that served as control subjects.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-1099800411405030">
<title>TPQ Assessment</title>
<p>The intravenous heroin addicts had significantly higher mean scores for NS (21.22) and HA (18.24) compared to the controls (12.46 and 14.36, respectively), as shown in <xref ref-type="table" rid="table3-1099800411405030">Table 3</xref>
. Although the control group scored higher in RD (17.6) than the intravenous heroin addicts (13.75), the difference between the two groups was not statistically significant.</p>
<table-wrap id="table3-1099800411405030" position="float">
<label>Table 3.</label>
<caption>
<p>Comparison of Mean TPQ Scores Among IVDUs and Controls</p>
</caption>
<graphic alt-version="no" alternate-form-of="table3-1099800411405030" position="float" xlink:href="10.1177_1099800411405030-table3.tif" xlink:type="simple"/>
<table>
<thead>
<tr>
<th colspan="1" rowspan="2">TPQ Scales and Subscales</th>
<th align="center" colspan="3" rowspan="1">IVDUs (<italic>n</italic> = 93)</th>
<th colspan="3" rowspan="1">Controls (<italic>n</italic> = 101)</th>
<th colspan="1" rowspan="2">
<italic>p</italic> Value<sup><xref ref-type="table-fn" rid="table-fn5-1099800411405030">a</xref></sup>
</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1">Mean</th>
<th colspan="1" rowspan="1">
<italic>SD</italic>
</th>
<th colspan="1" rowspan="1">α</th>
<th align="center" colspan="1" rowspan="1">Mean</th>
<th align="center" colspan="1" rowspan="1">
<italic>SD</italic>
</th>
<th colspan="1" rowspan="1">α</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="8" rowspan="1">Novelty seeking (NS)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NS1</td>
<td colspan="1" rowspan="1">4.31</td>
<td colspan="1" rowspan="1">1.95</td>
<td colspan="1" rowspan="1">0.42</td>
<td colspan="1" rowspan="1">4.12</td>
<td colspan="1" rowspan="1">1.45</td>
<td colspan="1" rowspan="1">0.07</td>
<td colspan="1" rowspan="1">−0.76</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NS2</td>
<td colspan="1" rowspan="1">3.68</td>
<td colspan="1" rowspan="1">2.13</td>
<td colspan="1" rowspan="1">0.38</td>
<td colspan="1" rowspan="1">1.64</td>
<td colspan="1" rowspan="1">1.46</td>
<td colspan="1" rowspan="1">0.53</td>
<td colspan="1" rowspan="1">−7.85<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NS3</td>
<td colspan="1" rowspan="1">5.37</td>
<td colspan="1" rowspan="1">1.26</td>
<td colspan="1" rowspan="1">0.42</td>
<td colspan="1" rowspan="1">2.82</td>
<td colspan="1" rowspan="1">1.59</td>
<td colspan="1" rowspan="1">0.48</td>
<td colspan="1" rowspan="1">−12.21<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NS4</td>
<td colspan="1" rowspan="1">7.83</td>
<td colspan="1" rowspan="1">2.00</td>
<td colspan="1" rowspan="1">0.45</td>
<td colspan="1" rowspan="1">3.87</td>
<td colspan="1" rowspan="1">1.59</td>
<td colspan="1" rowspan="1">0.24</td>
<td colspan="1" rowspan="1">−15.23<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NS</td>
<td colspan="1" rowspan="1">21.22</td>
<td colspan="1" rowspan="1">4.91</td>
<td colspan="1" rowspan="1">0.40</td>
<td colspan="1" rowspan="1">12.46</td>
<td colspan="1" rowspan="1">3.36</td>
<td colspan="1" rowspan="1">0.43</td>
<td colspan="1" rowspan="1">−14.60<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="8" rowspan="1">Harm avoidance (HA)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> HA1</td>
<td colspan="1" rowspan="1">4.54</td>
<td colspan="1" rowspan="1">1.83</td>
<td colspan="1" rowspan="1">0.43</td>
<td colspan="1" rowspan="1">3.55</td>
<td colspan="1" rowspan="1">1.79</td>
<td colspan="1" rowspan="1">0.42</td>
<td colspan="1" rowspan="1">−3.81<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> HA2</td>
<td colspan="1" rowspan="1">4.48</td>
<td colspan="1" rowspan="1">1.65</td>
<td colspan="1" rowspan="1">0.45</td>
<td colspan="1" rowspan="1">4.90</td>
<td colspan="1" rowspan="1">1.55</td>
<td colspan="1" rowspan="1">0.49</td>
<td colspan="1" rowspan="1">1.83</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> HA3</td>
<td colspan="1" rowspan="1">4.32</td>
<td colspan="1" rowspan="1">2.35</td>
<td colspan="1" rowspan="1">0.39</td>
<td colspan="1" rowspan="1">2.60</td>
<td colspan="1" rowspan="1">1.85</td>
<td colspan="1" rowspan="1">0.65</td>
<td colspan="1" rowspan="1">−5.55<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> HA4</td>
<td colspan="1" rowspan="1">4.95</td>
<td colspan="1" rowspan="1">2.61</td>
<td colspan="1" rowspan="1">0.43</td>
<td colspan="1" rowspan="1">3.30</td>
<td colspan="1" rowspan="1">2.29</td>
<td colspan="1" rowspan="1">0.60</td>
<td colspan="1" rowspan="1">−4.58<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> HA</td>
<td colspan="1" rowspan="1">18.24</td>
<td colspan="1" rowspan="1">5.02</td>
<td colspan="1" rowspan="1">0.40</td>
<td colspan="1" rowspan="1">14.36</td>
<td colspan="1" rowspan="1">5.20</td>
<td colspan="1" rowspan="1">0.77</td>
<td colspan="1" rowspan="1">−5.24<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="8" rowspan="1">Reward dependence (RD)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> RD1</td>
<td colspan="1" rowspan="1">3.05</td>
<td colspan="1" rowspan="1">1.17</td>
<td colspan="1" rowspan="1">0.46</td>
<td colspan="1" rowspan="1">4.35</td>
<td colspan="1" rowspan="1">0.74</td>
<td colspan="1" rowspan="1">0.03</td>
<td colspan="1" rowspan="1">−9.29<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> RD2</td>
<td colspan="1" rowspan="1">3.96</td>
<td colspan="1" rowspan="1">1.86</td>
<td colspan="1" rowspan="1">0.48</td>
<td colspan="1" rowspan="1">5.91</td>
<td colspan="1" rowspan="1">1.58</td>
<td colspan="1" rowspan="1">0.36</td>
<td colspan="1" rowspan="1">7.80</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> RD3</td>
<td colspan="1" rowspan="1">4.72</td>
<td colspan="1" rowspan="1">2.49</td>
<td colspan="1" rowspan="1">0.46</td>
<td colspan="1" rowspan="1">5.77</td>
<td colspan="1" rowspan="1">1.70</td>
<td colspan="1" rowspan="1">0.41</td>
<td colspan="1" rowspan="1">3.39</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> RD4</td>
<td colspan="1" rowspan="1">2.12</td>
<td colspan="1" rowspan="1">1.25</td>
<td colspan="1" rowspan="1">0.44</td>
<td colspan="1" rowspan="1">1.57</td>
<td colspan="1" rowspan="1">1.02</td>
<td colspan="1" rowspan="1">0.16</td>
<td colspan="1" rowspan="1">−3.24<sup><xref ref-type="table-fn" rid="table-fn6-1099800411405030">*</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> RD</td>
<td colspan="1" rowspan="1">13.75</td>
<td colspan="1" rowspan="1">3.70</td>
<td colspan="1" rowspan="1">0.51</td>
<td colspan="1" rowspan="1">17.6</td>
<td colspan="1" rowspan="1">2.49</td>
<td colspan="1" rowspan="1">0.22</td>
<td colspan="1" rowspan="1">8.59</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1099800411405030">
<p>
<italic>Note</italic>. <italic>Hypothesis 0</italic>: The means of scores in the healthy controls were at least as high as those in the IVDUs. <italic>Hypothesis 1</italic>: The means of scores in the healthy controls were lower than those in the IVDUs. TPQ = Tridimensional Personality Questionnaire; IVDUs = intravenous drug users. <sup>a</sup>Unpaired <italic>t</italic> test. For the two-tailed test, the critical value separating the lower 5% of the <italic>t</italic> distribution from the upper 95% was approximately −1.98. The null hypothesis was rejected when the observed value of <italic>t</italic> was less than −1.98.</p>
</fn>
<fn id="table-fn6-1099800411405030">
<p><sup>*</sup><italic>t</italic> ≤ −1.98.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-1099800411405030">
<title>Genotyping Analysis</title>
<p>We further confirmed the sequencing results with the DRD2 variation sites detected by PCR. The sequencing results showed 100% homology to DRD2, and the second PCR results also corresponded with the sequencing results. <xref ref-type="fig" rid="fig1-1099800411405030">Figure 1</xref>
 comprises an example of the sequencing results.</p>
<fig id="fig1-1099800411405030" position="float">
<label>Figure 1.</label>
<caption>
<p>DNA sequences of polymerase chain reaction (PCR) products. A, We aligned the nucleotide sequence of the PCR products obtained from sequencing using “BLAST,” software available from the National Center for Biotechnology Information (NCBI) that “finds regions of similarity between biological sequences” (<ext-link ext-link-type="uri" xlink:href="http://blast.ncbi.nlm.nih.gov/Blast.cgi" xlink:type="simple">http://blast.ncbi.nlm.nih.gov/Blast.cgi</ext-link>). We then compared the result with gel electrophoresis results for the selected samples that confirmed the variation sites at codons 154 and 141 of the human DRD2 for Val<sub>154</sub>Ile and Leu<sub>141</sub>Leu polymorphisms, respectively. B, A representative agarose gel electrophoresis of the allele-specific second PCR analysis of Set A (i) and Set B (ii) shows no variant-type alleles detected. C, Chromatogram of nucleotide sequence from the sample that shows homozygous wild-type alleles for Leu<sub>141</sub>Leu and Val<sub>154</sub>Ile polymorphisms. The positions of the Leu<sub>141</sub>Leu and Val<sub>154</sub>Ile polymorphisms are indicated by the vertical arrows.</p>
</caption>
<graphic alt-version="no" alternate-form-of="fig1-1099800411405030" position="float" xlink:href="10.1177_1099800411405030-fig1.tif" xlink:type="simple"/>
</fig>
</sec>
<sec id="section12-1099800411405030">
<title>Distribution of Allelic Variants and Frequencies of DRD2
</title>
<p>We compared the distribution of <italic>DRD2</italic> allelic variants among intravenous heroin addicts and healthy controls. We found that all of the addicts were wild type for allelic variants of Val<sub>96</sub>Ala, Val<sub>154</sub>Ile, Leu<sub>141</sub>Leu, and Pro<sub>310</sub>Ser. One intravenous heroin addict was homozygous for Ser<sub>311</sub>Cys variant, while 18% were heterozygous. For this same variant, 1% of healthy controls were homozygous, while 8% were heterozygous. However, there was no statistical difference between the two groups (Fisher’s exact χ<sup>2</sup> test; <italic>p</italic> &gt; .05). We observed a similar pattern of genotype distribution with respect to variants -141C Ins/Del and A-241G. In contrast to the 57% of healthy controls who were carriers of A2/A2 for the Taq1A polymorphism, only 30% of the intravenous heroin addicts had A2/A2 (Fisher’s exact χ<sup>2</sup> test, <italic>p</italic> &lt; .05).</p>
</sec>
<sec id="section13-1099800411405030">
<title>TPQ Scores of Intravenous Heroin Addicts With Different DRD2 Genotypes</title>
<p>We regrouped the intravenous heroin addicts according to their genotype status for variants Ser<sub>311</sub>Cys, TaqIA, -141C Ins/Del, and A-241G and compared the TPQ scores among the genotype groups using Fisher’s exact χ<sup>2</sup>.</p>
<p>For TaqIA polymorphism, we found a significant difference in RD3 scores among the three genotype variants, with scores for both of the A1+ carrier groups lower than those of the A1− carriers. We found no significant differences among the groups for the remaining RD subscales.</p>
<p>For -141 Ins/Del polymorphism, NS1 scores differed significantly among the three genotype groups (ANOVA; <italic>p</italic> = .027). The rest of the NS subscale scores were inconsistent and there were no statistically significant differences among the groups (ANOVA; <italic>p</italic> &gt; .05).</p>
<p>For A-241G polymorphism, we found significant differences among the three genotype groups for total NS (ANOVA; <italic>p</italic> = .049) and RD1 (ANOVA; <italic>p</italic> = 0.031). Scores for the rest of the scales were inconsistent and did not differ significantly among the groups.</p>
</sec>
</sec>
<sec id="section14-1099800411405030">
<title>Discussion</title>
<sec id="section15-1099800411405030">
<title>TPQ Assessment</title>
<p>We conducted the TPQ analysis to investigate the influence of personality on the risk-taking behaviors associated with intravenous heroin addicts. According to <xref ref-type="bibr" rid="bibr9-1099800411405030">Cloninger (1987b)</xref>, the scales measure different aspects of temperament that are associated with the following distinct neurotransmitters: dopamine for the NS scale, serotonin for the HA scale, and norepinephrine for the RD scale. In our study, the intravenous heroin addicts scored higher for NS and HA but lower for RD than the healthy controls. These findings suggest that the intravenous heroin addicts might have a higher level of dopamine and serotonin activity and a lower level of norepinephrine activity. This imbalance in neurotransmitters prompts the addict to seek substitute substances, which eventually leads to cravings.</p>
<p>NS4 (disorderliness) and NS2 (impulsiveness) are the two NS subscales for which the differences between the addicts and controls were the most significant. The NS scale is thought to reflect the brain’s incentive and behavior activation, which, as mentioned above, is associated with the dopamine system (<xref ref-type="bibr" rid="bibr2-1099800411405030">Bardo, Donohew, &amp; Harrington, 1996</xref>). Individuals with high NS scores readily engage in new interests and activities but tend to neglect details and are quickly distracted or bored (<xref ref-type="bibr" rid="bibr8-1099800411405030">Cloninger, 1987a</xref>; <xref ref-type="bibr" rid="bibr10-1099800411405030">Cloninger, Sigvardsson, Przybeck, &amp; Svrakic, 1995</xref>). Drug seeking is mediated by NS. Higher NS scores are also associated with the impulsive-aggressive antisocial personality disorder seen in alcoholism (<xref ref-type="bibr" rid="bibr31-1099800411405030">Tikkanen, Holi, Lindberg, &amp; Virkkunen, 2007</xref>). In addition, <xref ref-type="bibr" rid="bibr35-1099800411405030">Volkow et al. (2002)</xref> attributed vulnerability to addiction to persistently low D2 receptor availability. <xref ref-type="bibr" rid="bibr12-1099800411405030">Dalley et al.’s (2007)</xref> findings of reduced D2 receptor availability in the ventral striatum of highly impulsive rats support this hypothesis.</p>
<p>Our study also showed a higher score on the HA scale among intravenous heroin addicts compared to control subjects. <xref ref-type="bibr" rid="bibr9-1099800411405030">Cloninger (1987b)</xref> suggests that individuals with high scores on both NS and HA tend to be more uncertain and indecisive. This hypothesis is consistent with other studies showing that substance-dependent individuals often have impaired cognitive functions (<xref ref-type="bibr" rid="bibr3-1099800411405030">Bechara et al., 2001</xref>) and motor impulsivity (<xref ref-type="bibr" rid="bibr34-1099800411405030">Verdejo-Garcia &amp; Perez-Garcia, 2007</xref>). <xref ref-type="bibr" rid="bibr31-1099800411405030">Tikkanen, Holi, Lindberg, and Virkkunen (2007)</xref> suggest that the harm-avoidance extremes are associated with antisocial personality disorder and an increased likelihood of committing different types of violence. This finding may explain, at least in part, why the majority of the intravenous heroin addicts in the current study had criminal records and 76% had been imprisoned. Among all HA subscales, shyness with strangers (H3) recorded the most significant difference between the intravenous heroin addicts and control subjects. <xref ref-type="bibr" rid="bibr18-1099800411405030">Gorwood, Wohl, Le Strat, and Rouillon (2007)</xref> suggested that antisocial personality disorder is the most important risk factor for alcohol or drug abuse or dependence in a gene-environment interaction.</p>
<p>In our study, addicts scored lower on all subscales of RD than control subjects, however the differences were not significant for two of the subscales. Researchers have hypothesized that individuals with low scores on the RD scale are impaired in their responsiveness to verbal approval and social reinforcement and have poor persistence (<xref ref-type="bibr" rid="bibr9-1099800411405030">Cloninger, 1987b</xref>). Further, they demonstrate little tolerance for the unpredictable frustrations of life (<xref ref-type="bibr" rid="bibr7-1099800411405030">Chih-Hung et al., 2006</xref>). Abusing drugs might, therefore, serve as a satisfactory source for novelty and esteem without producing unpredictable frustration.</p>
<p>Overall, the TPQ result for the intravenous heroin addicts shows their tendencies to be neurotic, explorative, reckless, carefree, uninhibited, and more prone toward self-destructive behavior. These personality traits might put them at higher risk for developing addiction.</p>
</sec>
<sec id="section16-1099800411405030">
<title>Distribution of Allelic Variants and Frequencies of DRD2
</title>
<p>We found a significant difference in the frequency of TaqIA between intravenous heroin addicts and healthy controls. This finding is in accordance with previous reports that polymorphism of the <italic>DRD2</italic> increases the risk of addiction and has been associated with vulnerability to drug abuse and addictive behavior (<xref ref-type="bibr" rid="bibr4-1099800411405030">Berggren et al., 2006</xref>). Since the early 1990s, researchers have associated genetic polymorphism of DRD2 with alcoholism, specifically the TaqIA A1 allele (<xref ref-type="bibr" rid="bibr4-1099800411405030">Berggren et al., 2006</xref>; <xref ref-type="bibr" rid="bibr6-1099800411405030">Blum et al, 1990</xref>; <xref ref-type="bibr" rid="bibr24-1099800411405030">Noble, 1997</xref>, <xref ref-type="bibr" rid="bibr25-1099800411405030">2000</xref>). Results of the current study suggest that the same allele is associated with the development of drug addiction.</p>
<p>In this study, 70% of intravenous heroin addicts carried the A1+ allele (combined A1/A1 and A1/A2 genotypes) compared to 43% in the control group. This finding supports the theory that DRD2 TaqIA polymorphism A1 carriers are more vulnerable to becoming polysubstance dependant (<xref ref-type="bibr" rid="bibr11-1099800411405030">Comings, Muhleman, Ahn, Gysin, &amp; Flanagan, 1994</xref>; <xref ref-type="bibr" rid="bibr26-1099800411405030">O’Hara et al., 1993</xref>; <xref ref-type="bibr" rid="bibr29-1099800411405030">Smith et al., 1992</xref>). Similarly, <xref ref-type="bibr" rid="bibr22-1099800411405030">Lawford et al. (2000)</xref> found the prevalence of the A1 alleles to be significantly higher in Caucasian opioid-dependent patients compared to 50 unrelated Caucasian controls. None of the controls exceeded hazardous drinking levels and none were current smokers or illicit drug users. These investigators found strong associations between the minor A1 allele of <italic>DRD2</italic> and substance dependence, suggesting that DRD2 confers susceptibility to drug disorders.</p>
<p>Another variation of the <italic>DRD2</italic> gene that researchers have found to be associated with drug addiction as well as alcoholism is Ser<sub>311</sub>Cys. Investigators have hypothesized that this variant largely prevents signal transduction following receptor activation (<xref ref-type="bibr" rid="bibr17-1099800411405030">Goldman, Urbanek, Guenther, Robin, &amp; Long, 1998</xref>). In the current study, although the intravenous heroin addicts recorded a higher percentage of the variants compared to controls, the difference was not significant. This result was consistent with a large association and sib-pair linkage analysis that <xref ref-type="bibr" rid="bibr17-1099800411405030">Goldman et al. (1998)</xref> performed in American Indian isolates where the genotyping results revealed no significant association of Ser<sub>311</sub>Cys with alcoholism or substance use disorders.</p>
<p>As for the polymorphism of -141C Ins/Del, we found no significant differences between intravenous heroin addicts and control subjects. This finding supported the work by <xref ref-type="bibr" rid="bibr15-1099800411405030">Gelernter and Kranzler (1999)</xref>, who concluded there was no effect of -141C Ins/Del polymorphisms on risk for alcohol dependence or severity of alcohol dependence. Another variant found in the promoter region, A-241G, showed a similar pattern, and we identified no significant differences between the intravenous heroin addicts and the control group.</p>
<p>We detected no variants for four other allelic variants of the <italic>DRD2</italic> gene: Val<sub>96</sub>Ala, Val<sub>154</sub>Ile (from exon 3 to 4), Leu<sub>141</sub>Leu, and Pro<sub>310</sub>Ser (from exon 7) in either intravenous heroin addicts or controls.</p>
</sec>
<sec id="section17-1099800411405030">
<title>TPQ Scores of Intravenous Heroin Addicts With Different DRD2 Genotypes</title>
<p>For the TaqIA polymorphism, carriers of both A1+ variants showed higher scores on most of the NS subscales than A1− carriers. This finding shows that TaqIA AI+ is associated with drug addiction. However, the differences were all statistically insignificant. This lack of significance might be due to the large differences in numbers of subjects among the three genotype groups, with only 28 carriers of A2/A2 and 11 carriers of A1/A1 allele as compared to 54 carriers of A1/A2.</p>
<p>Most of the results for the HA and RD scales were inconsistent for all groups and showed no significant differences. However, the -141C Ins/Del polymorphism was associated with consistent scores on HA, with the variant groups scoring higher than the wild-type group, with the exception of HA2, for which the Del/Del group scored highest. Harm avoidance is mainly related to serotogenic activity, and the tendency of the intravenous drug user to avoid harm results in them having antisocial personality types (<xref ref-type="bibr" rid="bibr31-1099800411405030">Tikkanen et al., 2007</xref>), a quality that the NS scale also measures, in part.</p>
</sec>
</sec>
<sec id="section18-1099800411405030">
<title>Limitations</title>
<p>The control group was not age matched as they were healthy university students and were predisposed to different environmental cues compared to the intravenous heroin addicts and thus may not be the best comparison group. Perhaps, being exposed to the same circumstances as experienced by the intravenous heroin addicts, the healthy controls could become dependent on substances at a later point in their life. Therefore, it is recommended that further studies should employ gene-environment interaction approach to study factors associated with addictive behaviors.</p>
</sec>
<sec id="section19-1099800411405030">
<title>Conclusion</title>
<p>In this study, we found the <italic>TaqIA</italic> A1 allele of the <italic>DRD2</italic> gene to be present at a significantly higher percentage among intravenous heroin addicts compared to the control group. This result supports the hypothesis that the <italic>DRD2</italic> A1+ allele confers an increase in vulnerability to drug addiction and other related addictive behaviors (<xref ref-type="bibr" rid="bibr5-1099800411405030">Blum et al., 1996</xref>). Screening of this marker would be useful in identifying individuals at risk for drug addiction and in determining the choice for subsequent treatment. <xref ref-type="bibr" rid="bibr22-1099800411405030">Lawford et al. (2000)</xref> reported that they found the poorest rate of treatment success (42.1 in patients with <italic>DRD2</italic> A1+ allele %), followed by patients who had dropped out of the methadone program (22.7%). This finding suggests that a pharmacogenetic approach may enhance the treatment of opioid dependence.</p>
<p>The tridimensional personality model may provide a basis for analyzing the interaction between behavioral traits and environmental stimuli to predict individual susceptibility to addictive behavior (<xref ref-type="bibr" rid="bibr1-1099800411405030">Ball, 2005</xref>; <xref ref-type="bibr" rid="bibr19-1099800411405030">Goudriaan, Oosterlaan, de Beurs, &amp; Van den Brink, 2004</xref>). The TTPQ screening may also provide valuable information for treatment purposes, as researchers have found differences in treatment outcomes to be associated with personality disorders (<xref ref-type="bibr" rid="bibr33-1099800411405030">Van den Bosch &amp; Verheul, 2007</xref>).</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We would like to thank the participants, personnel in charge at the drop-in shelters, and doctor at Klinik Dr. Khafidz for their contributions to the study.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-1099800411405030">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1099800411405030">
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by a grant from the Ministry of Science, Technology and Innovation, Malaysia, and Universiti Teknologi MARA (UiTM). The grant provider had no further role in study design; in the collection, analysis or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ball</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Personality traits, problems, and disorders: Clinical applications to substance use disorders</article-title>. <source>Journal of Research in Personality</source>, <volume>39</volume>, <fpage>84</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr2-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Bardo</surname>
<given-names>M. T.</given-names>
</name>
<name name-style="western">
<surname>Donohew</surname>
<given-names>R. L.</given-names>
</name>
<name name-style="western">
<surname>Harrington</surname>
<given-names>N. G.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Psychobiology of novelty seeking and drug seeking behavior</article-title>. <source>Behavioural Brain Research</source>, <volume>77</volume>, <fpage>23</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr3-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Bechara</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Dolan</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Denburg</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Hindes</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Anderson</surname>
<given-names>S. W.</given-names>
</name>
<name name-style="western">
<surname>Nathan</surname>
<given-names>P. E.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers</article-title>. <source>Neuropsychologia</source>, <volume>39</volume>, <fpage>376</fpage>–<lpage>389</lpage>.</citation>
</ref>
<ref id="bibr4-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Berggren</surname>
<given-names>U.</given-names>
</name>
<name name-style="western">
<surname>Fahlke</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Aronsson</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Karanti</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Eriksson</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Blennow</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname> Balldin</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>The TAQI DRD2 A1 allele is associated with alcohol-dependence although its effect size is small</article-title>. <source>Alcohol</source>, <volume>41</volume>, <fpage>479</fpage>–<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr5-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Blum</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Braverman</surname>
<given-names>E. R.</given-names>
</name>
<name name-style="western">
<surname>Wood</surname>
<given-names>R. C.</given-names>
</name>
<name name-style="western">
<surname>Gill</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Chen</surname>
<given-names>T. J. H.</given-names>
</name>
<name name-style="western">
<surname> Cull</surname>
<given-names>J. G.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report</article-title>. <source>Pharmacogenetics</source>, <volume>6</volume>, <fpage>287</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr6-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Blum</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Noble</surname>
<given-names>E. P.</given-names>
</name>
<name name-style="western">
<surname>Sheridan</surname>
<given-names>P. J.</given-names>
</name>
<name name-style="western">
<surname>Montgomery</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Ritchie</surname>
<given-names>T.</given-names>
</name>
<name name-style="western">
<surname>Jagadeeswaran</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname> Cohn</surname>
<given-names>J. B.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Allelic association of human dopamine D2 receptor gene in alcoholism</article-title>. <source>Journal of the American Medical Association</source>, <volume>263</volume>, <fpage>2055</fpage>–<lpage>2060</lpage>.</citation>
</ref>
<ref id="bibr7-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chih-Hung</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Ju-Yu</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Cheng-Chung</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Sue-Huei</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Kuanyi</surname>
<given-names>W.</given-names>
</name>
<name name-style="western">
<surname>Cheng-Fang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Tridimensional personality of adolescents with internet addiction and substance use experience</article-title>. <source>Canadian Journal of Psychiatry</source>, <volume>51</volume>, <fpage>887</fpage>–<lpage>894</lpage>.</citation>
</ref>
<ref id="bibr8-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cloninger</surname>
<given-names>C. R.</given-names>
</name>
</person-group> (<year>1987a</year>). <article-title>Neurogenetic adaptive mechanisms in alcoholism</article-title>. <source>Science</source>, <volume>236</volume>, <fpage>410</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr9-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cloninger</surname>
<given-names>C. R.</given-names>
</name>
</person-group> (<year>1987b</year>). <article-title>A systematic method for clinical description and classification of personality variants: A proposal</article-title>. <source>Archives of General Psychiatry</source>, <volume>44</volume>, <fpage>573</fpage>–<lpage>588</lpage>.</citation>
</ref>
<ref id="bibr10-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cloninger</surname>
<given-names>C. R.</given-names>
</name>
<name name-style="western">
<surname>Sigvardsson</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Przybeck</surname>
<given-names>T. R.</given-names>
</name>
<name name-style="western">
<surname>Svrakic</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Personality antecedents of alcoholism in a national area probability sample</article-title>. <source>European Archives of Psychiatry and Clinical Neuroscience</source>, <volume>245</volume>, <fpage>239</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr11-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Comings</surname>
<given-names>D. E.</given-names>
</name>
<name name-style="western">
<surname>Muhleman</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Ahn</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Gysin</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Flanagan</surname>
<given-names>S. D.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>The dopamine D2 receptor gene: A genetic risk factor in substance abuse</article-title>. <source>Drug and Alcohol Dependence</source>, <volume>34</volume>, <fpage>175</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr12-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Dalley</surname>
<given-names>J. W.</given-names>
</name>
<name name-style="western">
<surname>Fryer</surname>
<given-names>T. D.</given-names>
</name>
<name name-style="western">
<surname>Brichard</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Robinson</surname>
<given-names>E. S. J.</given-names>
</name>
<name name-style="western">
<surname>Theobald</surname>
<given-names>D. E. H.</given-names>
</name>
<name name-style="western">
<surname>Laane</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement</article-title>. <source>Science</source>, <volume>315</volume>, <fpage>1267</fpage>–<lpage>1270</lpage>.</citation>
</ref>
<ref id="bibr13-1099800411405030">
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Dawson-Sanders</surname>
<given-names>B.</given-names>
</name>
<name name-style="western">
<surname>Trapp</surname>
<given-names>R. G.</given-names>
</name>
</person-group> (<year>1994</year>). <source>Basic and clinical biostatistics</source>
(<edition>3rd ed</edition>.). <publisher-loc>Norwalk, CT</publisher-loc>: <publisher-name>Appleton &amp; Lange</publisher-name>.</citation>
</ref>
<ref id="bibr14-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Foll</surname>
<given-names>B. L.</given-names>
</name>
<name name-style="western">
<surname>Gallo</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Strat</surname>
<given-names>Y. L.</given-names>
</name>
<name name-style="western">
<surname>Lu</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Gorwood</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Genetics of dopamine receptors and drug addiction: A comprehensive review</article-title>. <source>Behavioural Pharmacology</source>, <volume>20</volume>, <fpage>1</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr15-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Gelernter</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Kranzler</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>D2 dopamine receptor gene (DRD2) allele and haplotype frequencies in alcohol dependent and control subjects: No association with phenotype or severity of phenotype</article-title>. <source>Neuropsychopharmacology</source>, <volume>20</volume>, <fpage>640</fpage>–<lpage>649</lpage>.</citation>
</ref>
<ref id="bibr16-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Gerra</surname>
<given-names>G. S.</given-names>
</name>
<name name-style="western">
<surname>Bertacca</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Zaimovic</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Pirani</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Branchi</surname>
<given-names>B.</given-names>
</name>
<name name-style="western">
<surname>Ferri</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Relationship of personality traits and drug of choice by cocaine addicts and heroin addicts</article-title>. <source>Substance Use &amp; Misuse</source>, <volume>43</volume>, <fpage>317</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr17-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Goldman</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Urbanek</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Guenther</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Robin</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Long</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>A functionally deficient DRD2 variant [Ser311Cys] is not linked to alcoholism and substance abuse</article-title>. <source>Alcohol</source>, <volume>16</volume>, <fpage>47</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr18-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Gorwood</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Wohl</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Le Strat</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Rouillon</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Gene-environment interactions in addictive disorders: Epidemiological and methodological aspects</article-title>. <source>Comptes Rendus Biologies</source>, <volume>330</volume>, <fpage>329</fpage>–<lpage>338</lpage>.</citation>
</ref>
<ref id="bibr19-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Goudriaan</surname>
<given-names>A. E.</given-names>
</name>
<name name-style="western">
<surname>Oosterlaan</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>de Beurs</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Van den Brink</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Pathological gambling: A comprehensive review of biobehavioral findings</article-title>. <source>Neuroscience and Biobehavioral Reviews</source>, <volume>28</volume>, <fpage>123</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr20-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hou</surname>
<given-names>Q. F.</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>S. B.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Potential association of DRD2 and DAT1 genetic variation with heroin dependence</article-title>. <source>Neuroscience Letters</source>, <volume>464</volume>, <fpage>127</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr21-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kreek</surname>
<given-names>M. J.</given-names>
</name>
<name name-style="western">
<surname>Bart</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Lilly</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Laforge</surname>
<given-names>K. S,</given-names>
</name>
<name name-style="western">
<surname>Nielsen</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Pharmacogenetics and human molecular genetics of opiate and cocaine addiction and their treatments</article-title>. <source>Pharmacological Reviews</source>, <volume>57</volume>, <fpage>1</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr22-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lawford</surname>
<given-names>B. R.</given-names>
</name>
<name name-style="western">
<surname>Young</surname>
<given-names>R. M.</given-names>
</name>
<name name-style="western">
<surname>Noble</surname>
<given-names>E. P.</given-names>
</name>
<name name-style="western">
<surname>Sargent</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Rowell</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Shadforth</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname> Ritchie</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>The D(2) dopamine receptor A(1) allele and opioid dependence: Association with heroin use and response to methadone treatment</article-title>. <source>American Journal of Medical Genetics</source>, <volume>96</volume>, <fpage>592</fpage>–<lpage>598</lpage>.</citation>
</ref>
<ref id="bibr23-1099800411405030">
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Moyer</surname>
<given-names>P.A.</given-names>
</name>
</person-group> (<year>1992</year>). <source>Substance abuse. A multidimensional assessment and treatment approach</source>
(<edition>1st ed</edition>.). <publisher-loc>New York</publisher-loc>: <publisher-name>SLACK Inc</publisher-name>.</citation>
</ref>
<ref id="bibr24-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Noble</surname>
<given-names>E. P.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Phenotypic expression of the D2 dopamine receptor: A reinforcement of reward gene?</article-title> <source>Biological Psychiatry</source>, <volume>295</volume>, <fpage>42</fpage>.</citation>
</ref>
<ref id="bibr25-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Noble</surname>
<given-names>E. P.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: A review</article-title>. <source>European Psychiatry</source>, <volume>15</volume>, <fpage>79</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr26-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>O’Hara</surname>
<given-names>B. F.</given-names>
</name>
<name name-style="western">
<surname>Smith</surname>
<given-names>S. S.</given-names>
</name>
<name name-style="western">
<surname>Bird</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Persico</surname>
<given-names>A. M.</given-names>
</name>
<name name-style="western">
<surname>Suarez</surname>
<given-names>B. K.</given-names>
</name>
<name name-style="western">
<surname>Cutting</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Dopamine D2 receptor RFLPs, haplotypes and their association with substance use in Black and Caucasian research volunteers</article-title>. <source>Human Heredity</source>, <volume>43</volume>, <fpage>209</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr27-1099800411405030">
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Smith</surname>
<given-names>D. E.</given-names>
</name>
<name name-style="western">
<surname>Seymour</surname>
<given-names>R. B.</given-names>
</name>
</person-group> (<year>2001</year>). <source>Clinician’s guide to substance abuse</source>
<publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>.</citation>
</ref>
<ref id="bibr28-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Smith</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Watson</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Gates</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Ball</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Foxcroft</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: A HuGE gene-disease association review</article-title>. <source>American Journal of Epidemiology</source>, <volume>167</volume>, <fpage>125</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr29-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Smith</surname>
<given-names>S. S.</given-names>
</name>
<name name-style="western">
<surname>O’Hara</surname>
<given-names>B. F.</given-names>
</name>
<name name-style="western">
<surname>Persico</surname>
<given-names>A. M.</given-names>
</name>
<name name-style="western">
<surname>Gorelick</surname>
<given-names>D. A.</given-names>
</name>
<name name-style="western">
<surname>Newlin</surname>
<given-names>D. B.</given-names>
</name>
<name name-style="western">
<surname>Vlahov</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Genetic vulnerability in drug abuse: The dopamine D2 receptor TaqI B RFLP is more frequent in polysubstance abusers</article-title>. <source>Archives of General Psychiatry</source>, <volume>49</volume>, <fpage>723</fpage>–<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr30-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Spitz</surname>
<given-names>M. R.</given-names>
</name>
<name name-style="western">
<surname>Shi</surname>
<given-names>H.</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Hudmon</surname>
<given-names>K. S.</given-names>
</name>
<name name-style="western">
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name name-style="western">
<surname>Chamberlain</surname>
<given-names>R. M.</given-names>
</name>
<name name-style="western">
<surname> Wu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients</article-title>. <source>Journal of the National Cancer Institute</source>, <volume>90</volume>, <fpage>359</fpage>–<lpage>363</lpage>.</citation>
</ref>
<ref id="bibr31-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tikkanen</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Holi</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Lindberg</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Virkkunen</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Tridimensional Personality Questionnaire data on alcoholic violent offenders: Specific connections to severe impulsive cluster B personality disorders and violent criminality</article-title>. <source>BioMed Central Psychiatry</source>, <volume>7</volume>, <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr32-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tyndale</surname>
<given-names>R. F.</given-names>
</name>
<name name-style="western">
<surname>Droll</surname>
<given-names>K. P.</given-names>
</name>
<name name-style="western">
<surname>Sellers</surname>
<given-names>E. M.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Genetically deficient CYP2D6 metabolism provides protection against oral dependence</article-title>. <source>Pharmacogenetics</source>, <volume>7</volume>, <fpage>375</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr33-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Van den Bosch</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Verheul</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Patients with addiction and personality disorder: Treatment outcomes and clinical implications</article-title>. <source>Current Opinions in Psychiatry</source>, <volume>20</volume>, <fpage>67</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr34-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Verdejo-Garcia</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Perez-Garcia</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Profile of executive deficits in cocaine and heroin polysubstance users: Common and differential effects on separate executive components</article-title>. <source>Psychopharmacology</source>, <volume>517−530</volume>, <fpage>190</fpage>.</citation>
</ref>
<ref id="bibr35-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Volkow</surname>
<given-names>N. D.</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>G. J.</given-names>
</name>
<name name-style="western">
<surname>Fowler</surname>
<given-names>J. S.</given-names>
</name>
<name name-style="western">
<surname>Thanos</surname>
<given-names>P. P.</given-names>
</name>
<name name-style="western">
<surname>Logan</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Gatley</surname>
<given-names>S. J.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Brain DA D2 receptors predict reinforcing effects of stimulants in humans: Replication study</article-title>. <source>Synapse</source>, <volume>46</volume>, <fpage>79</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr36-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Vukov</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Baba-Milkic</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Lecic</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Personality dimensions of opiate addicts</article-title>. <source>Acta Psychiatrica Scandinavica</source>, <volume>91</volume>, <fpage>103</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr37-1099800411405030">
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Bertolino</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Fazio</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Blasi</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Rampino</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Romano</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname> Sadée</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>104</volume>, <fpage>20552</fpage>–<lpage>20557</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>